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has the potential to become an alternative treatment for 
glioblastoma.
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Introduction
Glioblastoma multiforme (GBM), a grade IV astrocytoma, 
is the most aggressive and malignant form of glioma. 
It accounts for 12–15% of all intracranial tumors and is 
characterized by molecular heterogeneity and resistance 
to therapy [1, 2]. Patients with high-grade glioma have a 
poor prognosis and median survival is <5 years depending 
on tumor grade, cytogenetic analysis, age, and performance 
status at the time of diagnosis [2]. Radiotherapy and/or 
concomitant chemotherapy with adjuvant temozolomide 
(TMZ) have become the standard of care in GBM [3, 4]. 
Temozolomide is a prodrug that undergoes metabolic acti-
vation following oral administration; thus its in vitro use is 
restricted [5]. Cisplatin is used to treat recurrent glioma; 
however, its clinical use is limited due to cellular resistance 
and dose-dependent toxicity in normal tissue [6–8].
The growth/development and internal organization of all 
animals depends on the maintenance of oxygen homeosta-
sis and depending on the organ size, function, and tissue 
location, a wide range of oxygen tension is encountered 
(0.002–10%; normal brain 16–21%) [9, 10]. A drop in 
oxygen partial pressure activates transcription of hypoxia 
inducible factor (HIF) leading to changes in cellular metab-
olism due to transcription of a wide array of genes such as 
EGFR (epidermal growth factor receptor), VEGFR (vascu-
lar endothelial growth factor receptor), and GLUT-1 (glu-
cose transporter-1) [9, 11, 12]. Hypoxia further promotes 
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the malignant phenotype of cancer cells, and hypoxic can-
cer cells often exhibit enhanced resistance to chemotherapy 
and radiation. Hypoxia is a predominant factor in GBM and 
plays an important role in tumor growth and progression 
[13]. Thus, it is important to establish the cytotoxicity of 
anti-cancer agents under hypoxia.
Asiatic acid (AA) is a pentacyclic triterpenoid extracted 
from Centella asiatica, native to countries including India 
and Sri Lanka [14, 15]. It displays a low side-effect profile 
and exhibits cytotoxicity against glioblastoma, breast, liver, 
and colon cancers [16]. In addition, evidence shows that 
AA can cross the BBB and it has been reported to induce 
apoptotic cell death in human hepatoma and malignant gli-
oma cells [17, 18].
In this study, the pharmacological effects of AA under 
normoxia (21%  O2) and hypoxia (1%  O2) have been inves-
tigated. To calculate drug efficacy, results have been com-
pared to the chemotherapeutic agent, cisplatin.
Materials and method
Cell culture
U87-MG (human Grade IV glioblastoma) and SVGp12 
(human Fetal glial) cell lines obtained from American Type 
Culture Collection (ATCC, UK) were maintained in a 37 °C 
humidified atmosphere containing 5%  CO2 in Eagles Mini-
mum Essential Media (EMEM), supplemented with 10% 
fetal bovine serum, 2  mM L-glutamine, 1% non-essential 
amino acids, and 1mM sodium pyruvate (Lonza, UK). For 
hypoxic experiments (1%  O2, 5%  CO2, 94%  N2), cells were 
seeded under normoxia (5%  CO2, 95% air) and allowed to 
adhere for a minimum of 2 h before transferring to hypoxia 
using an  InvivO2 400 hypoxia workstation (Baker Ruskinn, 
UK). Cells were allowed to acclimatize to hypoxia over-
night prior to treatment.
Cell viability assay
Cisplatin and AA (#P4394 and #A2612; Sigma Aldrich, 
UK) concentration–response curves in U87-MG and 
SVGp12 cell lines were performed under normoxia. Cells 
were seeded at a density of  103 cells/well in 96-well 
plates and cultured for 24  h prior to drug treatment 
 (10− 7–10− 4  M). Cell viability was measured at 24-, 48-, 
and 72-h post-treatment using  PrestoBlue® (Thermo Fisher 
Scientific, UK) by measuring fluorescence at an excitation/
emission of 535/612 nm after 1 h incubation at 37 °C using 
a GENios Pro plate reader (Tecan, UK). All treatments 
were performed in triplicate and a concentration–response 
analysis was performed (GraphPad Prism 5, GraphPad 
Software Inc., USA) to determine  EC50 and  EC25 concen-
trations for subsequent assays.
Cell proliferation assay
Cell proliferation was measured using carboxyfluores-
cein diacetate succinimidyl ester (CFDA-SE) dye (Cam-
bridge Bioscience, UK). Cells were seeded at a density of 
 105 cells/well in 6-well plates and 24 h later labeled with 
CFDA-SE (5  µM in 1X PBS) for 30  min. Fresh medium 
was added and cells were treated with  EC25 concentrations 
of cisplatin (2 μM) and AA (30 µM) for 24, 48, and 72 h 
under normoxia or hypoxia. Cells were harvested by trypsi-
nization and flow cytometry was performed on a Guava® 
easyCyte 12HT benchtop flow cytometer (Merck Millipore, 
UK). A total of 10,000 gated events representing the single 
cell population were analyzed to determine peak CFDA-SE 
fluorescence (488 nm) for each treatment population.
Cell cycle analysis
U87-MG cells were seeded at a density of  105 cells/well 
in 6-well plates and treated with 2 µM cisplatin and 30 µM 
AA, the  EC25 determined by the cell viability assay, for 
24, 48, 72, and 120 h under normoxia and hypoxia. Cells 
were harvested by trypsinization, fixed in 70% ethanol, and 
stained using 1X PBS containing RNase (250 µg/ml) and 
propidium iodide (5 µg/ml) for 30 min. Analysis was per-
formed on a  Guava® easyCyte 12HT benchtop flow cytom-
eter (Merck Millipore, UK). A total of 10,000 gated events 
representing the single cell population were analyzed to 
determine DNA content by fluorescence intensity (488 nm) 
for each treatment population.
Western blot analysis
U87-MG cells were treated for 48 h with the  EC50 concen-
tration of cisplatin (10 µM) and AA (50 µM) as determined 
by the cell viability assay. Cells were harvested by scrap-
ing into 250 µl of radio-immunoprecipitation assay buffer 
(RIPA) with protease and phosphatase inhibitor cocktails 
(Sigma Aldrich, UK) and solubilization achieved by 1  hr 
incubation on a rotating wheel at 4 °C. Protein content 
was normalized by BCA assay, samples (40 μg) separated 
by SDS–PAGE (12% bis-acrylamide), and transferred to 
PVDF nylon membranes (GE Healthcare Life Sciences, 
UK) using a wet transfer kit (Bio-Rad, UK). Membranes 
were blocked for 1 h at room temperature with 5% skimmed 
milk in Tris-buffered saline-0.1% Tween 20 (TBS-T), 
then incubated with cyclin B1 antibody (1:1000 dilution; 
Cell Signaling Technology, UK) in TBS-T overnight at 
4 °C with gentle shaking. Primary antibody detection was 
performed following incubation with HRP-conjugated 
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secondary antibody (1:2000 dilution; Cell Signaling Tech-
nology, UK) at room temperature for 1  h and visualized 
by enhanced chemiluminescence (Amersham prime ECL 
Prime-chemiluminescent agent; Bio-Rad, UK) on a Bio-
Rad Molecular Imager ChemiDoc™ XRS + System with 
Image Lab™ Software, UK. Following densitometry, bands 
were expressed as fold change compared to non-treated 
normoxic control.
Apoptosis assay
Cells were seeded at a density of  105 cells/well in 6-well 
plates and treated with 10  μM cisplatin and 50  μM AA. 
 EC50 was determined by the cell viability assay, under nor-
moxia and hypoxia. Following 24, 48, and 72  h of treat-
ment, cells were harvested by trypsinization and labeled 
using the Dead Cell Apoptosis Kit with Annexin-V/Alexa 
 Fluor® 488 and Propidium Iodide (Invitrogen/Life Tech-
nologies™, UK) as per the manufacturer’s instructions. 
Analysis was performed by flow cytometry on a FAC-
SAria (BD Bioscience, UK) and  Guava® easyCyte 12HT 
benchtop flow cytometer (Merck Millipore, UK). A total 
of 10,000 gated events were analyzed and the relative flu-
orescence (488  nm) of propidium iodide plotted against 
Annexin-V/Alexa  Fluor® to identify healthy and apoptotic 
cell populations.
Wound healing/migration assay
An in  vitro scratch assay was performed using U87-MG 
cells under normoxia and hypoxia. Cells were seeded at 
4.5 × 104 cells/well in a 24-well plate, incubated overnight, 
and the resulting cell monolayer was scraped in a single line 
using a sterile toothpick to create a scratch and the media 
was replaced to remove dislodged cells. Cells were treated 
with 2 μM cisplatin and 30 μM AA, the  EC25 concentra-
tion determined by the cell viability assay. The scratch was 
imaged immediately, and after 18 h of incubation, using a 
modified Zeiss Cell Observer imaging system using a Zeiss 
Plan-Apo 20 × 0.8 NA air objective (Zeiss, UK). Scratch 
diameter was measured using an average of six points on 
a minimum of three separate images per treatment using 
the Zeiss Zen desk software. Results were expressed as per-
centage closure vs non-treated control.
Statistical analysis
Statistical analysis was performed using one-way and two-
way ANOVA with Bonferroni’s post hoc test as described 
in GraphPad Prism software version 5 (GraphPad Soft-
ware, GraphPad Software Inc., USA). Significant differ-
ences were accepted for p < 0.05 and have been represented 
as *p < 0.05, **p < 0.01, and ***p < 0.001. Results were 
expressed as mean ± SEM of three individual experiments.
Results
Dose and time responses for the viability effect of asiatic 
acid in vitro
The potential of cisplatin and AA to affect U87-MG human 
glioblastoma cell viability was investigated in  vitro and 
compared to the non-cancerous SVGp12 cell line. A con-
centration- and time-dependent decrease in cell viability 
was observed for both cisplatin and AA (Fig.  1). While 
no overall significant difference was found between each 
of the treatments (p > 0.05), significant differences were 
observed between  EC50 values (Table 1). Following 24 h of 
treatment in the U87-MG cell line, the  EC50 value for AA 
was significantly lower than that of cisplatin (44 ± 20 vs. 
97 ± 11 μM respectively; p < 0.01). However, following 48 
and 72 h of treatment, the  EC50 value for cisplatin was sig-
nificantly lower than that of AA in U87-MG cells (7.4 ± 0.4 
vs. 47.4 ± 3.0 μM; p < 0.05 and 4.7 ± 1.0 vs. 59 ± 17.0 μM; 
p < 0.01 respectively).
As cell viability can be influenced by multiple factors, it 
was decided to examine the effects of AA on cell prolifera-
tion and apoptosis following 48 h of treatment using either 
the  EC50 or  EC25 as determined by the cell viability assays. 
Additionally, as the efficacy of treatment can be affected by 
oxygen levels in the tumor microenvironment, subsequent 
assays were performed under both normoxia (21%  O2) and 
hypoxia (1%  O2).
Effect of asiatic acid on U87‑MG cell proliferation
To investigate the effect of AA on U87-MG cell growth, 
a proliferation assay was performed. Following staining 
with CFDA-SE, under normoxia, flow cytometric analy-
sis showed a decrease in CFDA fluorescence in untreated 
cells over 72 h (Fig. 2a). Cells were treated with cisplatin 
and AA under normoxia and hypoxia using the  EC25 con-
centration determined by the cell viability assay. A signifi-
cant decrease in proliferation was noted in cisplatin-treated 
U87-MG cells under hypoxia at 48  h when compared to 
the non-treated normoxic (31.5 ± 7.0 vs. 14.7 ± 0.4%) and 
hypoxic (31.5 ± 7.0 vs. 13.4 ± 0.3%) controls (Fig.  2b, d, 
p < 0.05). AA treatment showed no significant decrease in 
proliferation under normoxia or hypoxia vs either control 
or cisplatin treatment (Fig. 2c, d). This result indicated that 
the effect of AA on cell viability was not due to a signifi-
cant decrease in cell proliferation. Similarly, AA did not 
reduce SVGp12 cell proliferation (see Online Resource 2).
182 Mol Cell Biochem (2017) 430:179–190
1 3
Cell cycle arrest in U87 cells following cisplatin 
and asiatic acid treatment
To further establish the effects of cisplatin and AA on cell 
growth, cell cycle arrest was measured by flow cytometry. 
Normoxic U87-MG cells treated with the  EC25 of cispl-
atin showed a significant decrease in the proportion of G0/
G1 phase cells compared to non-treated controls (Fig. 3a, 
b, and d; 30.0 ± 8.4% vs. 53.0 ± 9.6%; p < 0.05) with a 
concomitant increase in the proportion of cells in G2/M 
phase compared to non-treated controls (Fig. 3a, b, and d; 
58.9 ± 5.7% vs. 31.8 ± 8.7%; p < 0.01). AA had no signifi-
cant effect on U87-MG cell cycle distribution under either 
normoxia or hypoxia compared to control (Fig.  3c, d). 
Neither AA, nor cisplatin treatment at  EC25 induced apop-
tosis (see Online Resource 1).
Western blot analysis of cyclin B1 expression showed 
an increase in cyclin B1 levels in U87-MG cells following 
48-hour cisplatin treatment under normoxia (Fig. 4b), cor-
relating with the cell cycle arrest in G2/M in these cells. 
While the cyclin B1 levels following AA treatment were not 
significantly different from control under normoxia, they 
were significantly lower than following cisplatin treatment 
(Fig.  4b 0.24 ± 0.07-fold vs. 1.55 ± 0.22-fold respectively; 
p < 0.001). Under hypoxia, both non-treated (0.13 ± 0.05-
fold; p < 0.05) and cisplatin-treated (0.49 ± 0.23-fold; 
p < 0.01) cyclin B1 levels were significantly lower than 
their normoxic equivalents (Fig. 4b).
Fig. 1  Concentration- and 
time-dependent changes in cell 
viability following cisplatin and 
AA treatment at 24, 48, and 
72 h of (a and b) the SVGp12 
and (c and d) the U87-MG 
cell lines. Data represent 
mean ± SEM of three independ-
ent experiments. Statistical 
significance determined by 
ANOVA with Bonferroni’s post 
hoc test (p < 0.05)
Table 1  Cell viability  EC50 
values for cisplatin and AA 
under normoxia following 24, 
48, and 72 h of treatment
Data represent mean ± SEM of three independent experiments. Statistical significance determined by 
ANOVA with Bonferroni’s post hoc test (p < 0.05)
Normoxia Cisplatin
(μΜ)
Asiatic acid
(μΜ)
24 h 48 h 72 h 24 h 48 h 72 h
SVG p12 33.8 ± 7.9 11.2 ± 1.4 5.4 ± 0.5 50.3 ± 18.0 66.6 ± 7.6 56.6 ± 3.6
U87-MG 97.0 ± 11.7 7.4 ± 0.4 4.7 ± 1.0 44.3 ± 20.2 47.4 ± 3.1 59.0 ± 17.3
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Induction of apoptosis in U87‑MG cells
Having shown that cell proliferation and cell cycle are sig-
nificantly regulated by cisplatin but not by AA treatment, 
induction of apoptosis was examined over 72 h following 
treatment of cells with cisplatin and AA using the  EC50 
concentration determined by cell viability assays. The total 
apoptotic population was determined by combining the cell 
population staining positively for Annexin-V alone (early 
apoptosis) with that staining positively for both Annexin-V 
and PI (late apoptosis). The total apoptotic population fol-
lowing 48 h of drug treatment with AA under hypoxia was 
significantly greater than the equivalent treatment under 
normoxia (Fig. 5d; 207 ± 131-fold vs. 3.1 ± 0.3-fold respec-
tively; p < 0.001), in addition to both the normoxic (Fig. 5d 
16.8 ± 9.6-fold; p < 0.01) and hypoxic (Fig.  5d 0.8 ± 0.1-
fold; p < 0.001) populations following 48  h of cisplatin 
treatment.
Early-phase apoptosis significantly increased follow-
ing 72  h of AA treatment under normoxia in U87-MG 
cells when compared to non-treated controls (Fig.  5 
e 3.0 ± 0.8-fold; p < 0.01), a level of apoptosis that 
was significantly greater than the equivalent popula-
tion in SVGp12 cells (Fig.  5 e 1.0 ± 0.1-fold; p < 0.01). 
AA treatment also induced a significant increase in 
late-phase apoptosis compared to non-treated control 
following 24  h of treatment under normoxia (Fig.  5e 
5.9 ± 1.0-fold; p < 0.001). Interestingly, the proportion 
of late-phase apoptosis induced by AA treatment at both 
48 h (Fig. 5 e 4.4 ± 0.3-fold; p < 0.01) and 72 h (Fig.  5 
e 3.3 ± 0.2-fold; p < 0.001) under hypoxia was signifi-
cantly greater than the equivalent treatment under nor-
moxia (Fig. 5 e 48 h, 2.3 ± 0.3-fold; 72 h, 0.4 ± 0.1-fold).
Fig. 2  Effect of cisplatin and AA treatment on cell proliferation 
in U87-MG cells. Representative flow cytometric plots showing 
CFDA-SE fluorescence intensity in non-treated controls (a) immedi-
ately after staining with CFDA (gray fill) and at 24 (straight lines), 
48 (dashed lines), and 72 (dotted lines) hours and under normoxia; 
following 48  h of incubation for control (straight lines), cisplatin 
(dashed lines) and AA (dotted lines) treatments with non-treated 
control immediately after incubation with CFDA (gray fill) under 
normoxia (b) and hypoxia (c). Graphical representation of cell pro-
liferation as determined by mean CFDA-SE fluorescence intensity (d) 
following 48  h of treatment under normoxia and hypoxia. NT non-
treated, Cis Cisplatin, AA Asiatic acid. Data represent mean ± SEM 
of three independent experiments. Statistical significance determined 
by One-Way ANOVA with Dunnett’s post hoc test (p < 0.05)
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Wound healing/migration assay in U87‑MG cells
Finally, cell migration was examined using the wound 
healing assay to determine any effect of cisplatin or AA 
under normoxia and hypoxia. Under normoxia in non-
treated cells, the scratch completely closed during the 
18-h incubation (Fig.  6a, b). Treatment with cisplatin 
produced a small but significant reduction in wound heal-
ing compared to control (Fig. 6b, 97.0 ± 1.0%; p < 0.001), 
with AA producing a larger reduction in cell migration 
under the same condition compared to control (Fig.  6b, 
36.9 ± 0.7%; p < 0.001). Importantly, the reduction in 
migration produced by AA was significantly greater 
than the reduction produced by cisplatin treatment 
under normoxia (p < 0.001). Hypoxia itself significantly 
reduced wound healing in control cells when compared 
to normoxia (Fig. 6b, 26.9 ± 1.9% vs. 100% respectively; 
p < 0.001). Under hypoxia, neither drug treatment with 
cisplatin (33.3 ± 3.5%), nor AA (36.4 ± 3.7%) signifi-
cantly changed cell migration when compared to hypoxic 
control.
Fig. 3  Effect of cisplatin and AA treatment on cell cycle in U87-MG 
cells. Representative flow cytometric plots showing PI fluorescence 
intensity following 48 h incubation for (a) non-treated, (b) cisplatin, 
and (c) AA treatments under normoxia (n) and hypoxia (h). (d) Cell 
cycle analysis of U87-MG cells following 48 h of cisplatin treatment 
and AA treatment (white: control, gray: normoxia, black: hypoxia). 
Data represent mean ± SEM of three independent experiments. Statis-
tical significance determined by ANOVA with Bonferroni’s post hoc 
test (p < 0.05, dotted line; p < 0.01, solid line comparisons)
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Discussion
Cisplatin (cis-diamminedichloroplatinum) is a potent 
chemotherapeutic drug widely used for cancer treatment 
[7]. The clinical use of cisplatin includes treatment of sar-
comas; ovarian and cervical cancers; cancers of the bone, 
soft tissue, and blood; and pediatric solid tumors [19]. 
Cisplatin enters cells by passive diffusion and produces 
its cytotoxicity via DNA intercalation inducing apoptosis 
and changes in cell cycle [6, 20–23]. However, cisplatin 
efficacy is reduced under hypoxia [24], and its unfavorable 
toxicological profile characterized by nephrotoxicity, neu-
rotoxicity, nausea, vomiting, and immunosuppression limit 
its clinical usefulness [6, 25]. Additionally, the absorption 
of cisplatin into the perifocal tumor is hindered by the pres-
ence of the BBB [26]. In contrast, AA has been established 
as a potential therapeutic agent in many cancer types, has a 
low risk of severe side effects, anti-angiogenesis properties 
[27], and has shown to cross the BBB [28]. Thus, the main 
aim of this study was to investigate the anti-cancer effects 
of AA on glioblastoma cells in vitro under normoxia and 
hypoxia.
Both cisplatin and AA produced a decrease in U87-MG 
cell viability in a time- and concentration-dependent man-
ner. As cisplatin exerts its cytotoxicity by forming DNA 
lesions, this mechanism of action delayed reductions in cell 
viability until after 48 h of treatment [6, 29]. AA demon-
strated greater cytotoxicity in the U87-MG cell line than in 
SVGp12, a finding that correlates with a recent study which 
also observed consistently lower cell viability in U87-MG 
cells compared to SVGp12 cells [30]. It has been suggested 
that reduced cell viability following AA treatment is due to 
endoplasmic reticulum stress as a result of activated GRP-
78 and an increase in intracellular calcium level, which 
decreases the mitochondrial membrane potential, leading to 
cell death [17, 18].
Due to DNA intercalation, cisplatin is known to disrupt 
the cell cycle [31, 32], an effect replicated in this study 
where a reduction in the rate of proliferation of U87-MG 
cells and cell cycle arrest in the G2/M phase was observed 
under normoxia. Cyclin B1 and cyclin-dependent kinase 1 
(CDK1) specifically regulate cell’s entry into mitosis, and 
an increase in cyclin B1 expression observed by western 
blotting confirmed cell cycle arrest in the G2/M phase of 
Fig. 4  Western blot analysis for cyclin B1 expression in cisplatin- 
and AA-treated U87-MG cells under normoxia and hypoxia (a); 
graphical representation of fold change in cyclin B1 expression com-
pared to non-treated normoxia control (b). NT non-treated, Cis cispl-
atin, AA Asiatic acid. Data represent mean ± SEM of three independ-
ent experiments. Statistical significance determined by ANOVA with 
Bonferroni’s post hoc test (p < 0.05)
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cisplatin-treated cells under normoxia [33]. Although AA 
has formerly been reported to induce a G2/M phase arrest 
in RPMI 8226 cells [16] and S-G2/M arrest in MCF-7 and 
MDA-MB-231 breast cancer cell lines [34], in U87-MG 
cells under normoxia or hypoxia, AA did not show any sig-
nificant changes in cell proliferation or cell cycle distribu-
tion. This is in agreement with previous studies that used 
glioblastoma cell lines and found that AA inhibits cell via-
bility mainly via cell death, but their effects on cell prolif-
eration or cell cycle have not been reported [30].
Decrease in oxygen supply to cells leads to biochemi-
cal changes that either result in cell death or adaptation to 
hypoxia regulated by HIF-1α [35]. This effect is report-
edly due to the cyclin-dependent kinase inhibitor  p27Kip1 
that inhibits the activation of cyclin E-Cdk2 or cyclin 
D-Cdk4 complexes thus controlling cell cycle progression 
at G1 phase [36]. Hypoxia results in a slower cell cycle 
progression, whereas moderate hypoxia (e.g., 1%) induces 
pre-DNA-synthetic (pre-S-phase) arrest in cells, while 
cells in the other phases of cell cycle, progress to late G1 
phase before they arrest [37]. This transient arrest in G1 
phase has been described as a possible mechanism to pro-
tect cells from proceeding into the S phase, where they are 
more sensitive to hypoxia-related DNA injuries [38]. Cis-
platin treatment of U87-MG cells under hypoxia decreased 
cell proliferation; however, the number of cells arrested in 
G2/M phase of cell cycle following hypoxic cisplatin treat-
ment was lower than under normoxia. AA treatment under 
hypoxia did not produce significant changes in cell prolif-
eration or cell cycle; however, a greater population of cells 
Fig. 5  Induction of apoptosis following 48-h treatment of the 
U87-MG cell line under normoxia (n) and hypoxia (h) with cisplatin 
or AA. Representative dot plots showing fluorescence intensity of PI 
vs Annexin-V staining in (a) non-treated, (b) cisplatin, (c) AA. Rela-
tive proportion of total apoptotic U87-MG cells following 24, 48, and 
72 h of cisplatin and AA treatment under normoxia and hypoxia (d), 
data normalized to normoxic non-treated cells. Relative proportions 
of early and late apoptotic cells following 24, 48, and 72  h of AA 
treatment (e) under normoxia and hypoxia, data normalized to non-
treated SVGp12 cells. Data represent mean ± SEM of three independ-
ent experiments. Statistical significance determined by ANOVA with 
Bonferroni’s post hoc test (p < 0.05)
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was observed in the G0/G1 phase of cell cycle. The lower 
levels of cyclin B1 expression under hypoxia in comparison 
to normoxia along with an increase in cell populations at 
G0/G1 phase confirms that cells were not arrested in G2/M 
phase of cell cycle.
Under normoxia, a time-dependent increase in apoptosis 
was observed in U87-MG cells following cisplatin treat-
ment; a finding in agreement with previous studies con-
ducted using cisplatin [30, 39]. Cisplatin exerts an additive 
cytotoxic effect on cells as they proliferate and a prolonged 
exposure to cisplatin leads to apoptotic cell death [31]. Cell 
proliferation is an important factor for the cytotoxic effects 
of cisplatin due to its mechanism of action. As hypoxia 
results in slower cell proliferation, the total apoptotic 
population of cells following hypoxic cisplatin treatment 
was lower than normoxic. This finding has been confirmed 
in other studies where a reduced efficacy of cisplatin under 
hypoxia was observed [24, 40].
Early and late apoptotic cells are distinguished by a loss 
of membrane integrity and propidium iodide staining in 
late apoptotic cells [41]. A large proportion of SVGp12 and 
U87-MG cells were observed in late apoptosis, confirmed 
by Annexin-V and PI binding, following AA treatment 
under both normoxia and hypoxia. Interestingly, a time-
dependent shift in the proportion of cells in late apoptosis 
back into the early apoptotic quadrant was observed for 
normoxic SVGp12 and U87-MG cells following AA treat-
ment, possibly suggesting a loss of efficacy of AA treatment 
Fig. 6  Inhibition of wound healing/migration by cisplatin and AA 
treatment in U87-MG cells under normoxia and hypoxia. (a) Rep-
resentative microscopy images showing initial scratch and subse-
quent width following 18 h of incubation. (b) Graphical representa-
tion of wound healing following 18  h of treatment under normoxia 
and hypoxia with results expressed as a percentage of initial wound 
width. NT non-treated, Cis cisplatin, AA Asiatic acid. Data represent 
mean ± SEM of three independent experiments. Statistical signifi-
cance determined by One-Way ANOVA with Bonferroni’s post hoc 
test (p < 0.05)
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over time following a single-drug treatment. This is not a 
surprising result as AA has been shown in vivo to generate 
a large number of phase I metabolites, and additionally a 
number of cytochrome p450 enzymes such as CYP2C9 are 
known to be highly expressed in brain tumors [42, 43]. This 
effect was not observed following hypoxic AA treatment 
and a large number of late apoptotic cells were observed 
which did not change significantly over 72  h. AA causes 
DNA fragmentation and also induces a loss of phosphati-
dylserine symmetry that results in phosphatidylserine being 
exposed on the outer cell membrane [17, 34]. AA-mediated 
cell death in U87-MG cells involves caspase-9 and cas-
pase-3 activation and intracellular calcium release that trig-
gers a biochemical cascade resulting in calpain activation 
and subsequent cell death due to breakdown of the cellular 
architecture [17, 34, 44]. As AA cytotoxicity is not depend-
ent on cell proliferation, an overall increase in apoptotic 
population of AA-treated cells was observed under hypoxia 
in comparison to cisplatin.
The in vitro scratch assay is a method of studying cell 
migration. GBMs are characterized by an aggressively inva-
sive phenotype that leads to infiltration into the surround-
ing brain tissue, a characteristic which makes it difficult to 
eliminate with gross resection and chemotherapy, thus any 
treatment resulting in a decrease of the invasive phenotype 
may have therapeutic potential. When a cell monolayer is 
wounded or scratched, it responds to the cell–cell disrup-
tion by increasing growth factors at the wound site and ulti-
mately results in healing of the wound through migration 
and cell proliferation [45]. Microscopic analysis follow-
ing normoxic and hypoxic AA treatment showed rounded 
cells, a characteristic of apoptotic cell death [46]. A larger 
proportion of apoptotic cells were observed under hypoxia 
than under normoxia, suggesting again that AA does not 
regulate cell proliferation or cell cycle but instead exerts 
its cytotoxicity via inducing cell death. As cells prolifer-
ate slowly under hypoxia and cells may undergo cell cycle 
arrest or senescence, an overall reduction in wound healing 
was also observed vs normoxic control [47]. As cisplatin 
mainly exerts its cytotoxicity after 48 h of incubation, the 
lack of efficacy of cisplatin on wound healing under nor-
moxia may be explained in part by the shorter time scale 
used for these experiments.
Results of this study collectively demonstrate the 
cytotoxic potential of AA on in  vitro glioblastoma cells. 
Although AA did not regulate cell proliferation and cell 
cycle progression of SVGp12 and U87-MG cells, a higher 
proportion of cells underwent apoptosis under hypoxia. In 
contrast to cisplatin treatments under hypoxia, a greater 
efficacy of AA on induction of cellular apoptosis and a 
significant delay in wound healing were observed. With 
its reduced side effect profile and increased time course for 
cytotoxicity under both normoxia and hypoxia, these data 
suggest that AA has the potential to become an alternative 
therapy for the treatment of glioma.
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